← Back to Clinical Trials
Recruiting NCT05773885

NCT05773885 Telerehabilitation in People With Parkinson's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05773885
Status Recruiting
Phase
Sponsor IRCCS San Raffaele Roma
Condition Parkinson's Disease
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2022-09-01
Primary Completion 2025-03-30

Eligibility & Interventions

Sex All sexes
Min Age 30 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)Conventional rehabilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2022-09-01 with a primary completion date of 2025-03-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Although TeleRehabilitation (TR) is widely accepted as an appropriate model for the provision of professional health services in the field of physiotherapy, with already established standards, guidelines and policies, there are still few studies in the literature on the use of TR as a rehabilitation tool in people with Parkinson's Disease (PD). Therefore, further studies on the efficacy of TR in the management of motor and non-motor symptoms of PD are needed. The study TEMPO aims at assessing the efficacy (in terms of autonomy in carrying out the activities of daily life) of a home TR program based on serious games in people with PD compared to conventional day-hospital treatment.

Eligibility Criteria

Inclusion Criteria: * age between 30 and 80 years; * diagnosis of Parkinson's Disease according to the "Movement Disorders Society's diagnostic criteria"; * Hoehn \& Yahr (H\&Y) score between 2 and 3 (ON-state); * absence of dyskinesias assessed by the MDS-UPDRS with a score to items 4.1 and 4.2 ≤ 2; * absence of cognitive impairment measured by the MoCA total score ≥ 18; * stabilized drug treatment; * have access to the Internet for TR; * have a caregiver available during rehabilitation sessions in TR; * have sufficient cognitive and linguistic level to understand and comply with study procedures; * sign informed consent. Exclusion Criteria: * having any cognitive problems or low compliance that prevent using the TR system; * other neurological pathologies, psychiatric complications or personality disorders; * musculoskeletal diseases that impair movement; * presence of dyskinesias assessed by the MDS-UPDRS with a score to items 4.1 and 4.2 \> 2; * presence of cognitive impairment measured by the MoCA total score \< 18; * severe cognitive or linguistic deficits (inability to understand and comply with study procedures); * presence of blurred or low vision problems; * hearing and speech impairment affecting participation in the system; * absence of signature of the informed consent.

Contact & Investigator

Central Contact

Dr. Sanaz Pournajaf, DPT

✉ sanaz.pournajaf@sanraffaele.it

📞 +39 0652252405

Principal Investigator

Dr. Sanaz Pournajaf, DPT

PRINCIPAL INVESTIGATOR

IRCCS San Raffaele Roma

Frequently Asked Questions

Who can join the NCT05773885 clinical trial?

This trial is open to participants of all sexes, aged 30 Years or older, up to 80 Years, studying Parkinson's Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05773885 currently recruiting?

Yes, NCT05773885 is actively recruiting participants. Contact the research team at sanaz.pournajaf@sanraffaele.it for enrollment information.

Where is the NCT05773885 trial being conducted?

This trial is being conducted at Cassino, Italy, Rome, Italy.

Who is sponsoring the NCT05773885 clinical trial?

NCT05773885 is sponsored by IRCCS San Raffaele Roma. The principal investigator is Dr. Sanaz Pournajaf, DPT at IRCCS San Raffaele Roma. The trial plans to enroll 40 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology